Kathleen Mullane to Humans
This is a "connection" page, showing publications Kathleen Mullane has written about Humans.
Connection Strength
0.467
-
Remdesivir Use in the Setting of Severe Renal Impairment: A Theoretical Concern or Real Risk? Clin Infect Dis. 2021 12 06; 73(11):e3990-e3995.
Score: 0.028
-
Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial. Lancet Infect Dis. 2019 09; 19(9):1001-1012.
Score: 0.023
-
Management of Clostridioides (formerly Clostridium) difficile infection (CDI) in solid organ transplant recipients: Guidelines from the American Society of Transplantation Community of Practice. Clin Transplant. 2019 09; 33(9):e13564.
Score: 0.023
-
A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis of Clostridium difficile-associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation. Clin Infect Dis. 2019 01 07; 68(2):196-203.
Score: 0.022
-
Isavuconazole for treatment of rare invasive fungal diseases. Mycoses. 2018 Aug; 61(8):518-533.
Score: 0.022
-
Brincidofovir treatment of acyclovir-resistant disseminated varicella zoster virus infection in an immunocompromised host. Transpl Infect Dis. 2016 Oct; 18(5):785-790.
Score: 0.019
-
Surotomycin versus vancomycin for Clostridium difficile infection: Phase 2, randomized, controlled, double-blind, non-inferiority, multicentre trial. J Antimicrob Chemother. 2016 10; 71(10):2964-71.
Score: 0.019
-
Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections. Antimicrob Agents Chemother. 2015 Mar; 59(3):1435-40.
Score: 0.017
-
Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adults. J Infect Dis. 2013 Nov 01; 208(9):1375-85.
Score: 0.015
-
Renal impairment and clinical outcomes of Clostridium difficile infection in two randomized trials. Am J Nephrol. 2013; 38(1):1-11.
Score: 0.015
-
Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis. 2011 Sep; 53(5):440-7.
Score: 0.014
-
Fidaxomicin: first-in-class macrocyclic antibiotic. Expert Rev Anti Infect Ther. 2011 Jul; 9(7):767-77.
Score: 0.013
-
Posaconazole salvage therapy allows successful allogeneic hematopoietic stem cell transplantation in patients with refractory invasive mold infections. Transpl Infect Dis. 2007 Jun; 9(2):89-96.
Score: 0.010
-
A Phase 3, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate Safety, Tolerability, and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Allogeneic Hematopoietic Cell Transplant Recipients (PNEU-STEM). Clin Infect Dis. 2023 10 13; 77(8):1102-1110.
Score: 0.008
-
Pseudo-SARS. N Engl J Med. 2003 Aug 14; 349(7):709-11; author reply 709-11.
Score: 0.008
-
American Society for Transplantation and Cellular Therapy Series: #5-Management of Clostridioides difficile Infection in Hematopoietic Cell Transplant Recipients. Transplant Cell Ther. 2022 05; 28(5):225-232.
Score: 0.007
-
Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial. Nat Med. 2022 04; 28(4):823-830.
Score: 0.007
-
Cording in Disseminated Mycobacterium chelonae Infection in an Immunocompromised Patient. Lab Med. 2021 May 04; 52(3):e50-e52.
Score: 0.007
-
A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial of Presatovir for the Treatment of Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic-Cell Transplant Recipients. Clin Infect Dis. 2020 12 31; 71(11):2777-2786.
Score: 0.006
-
A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Lower Respiratory Tract. Clin Infect Dis. 2020 12 31; 71(11):2787-2795.
Score: 0.006
-
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2020 09 15; 324(11):1048-1057.
Score: 0.006
-
Changes in Intravenous Immunoglobulin Usage for Hypogammaglobulinemia After Implementation of a Stewardship Program. JCO Oncol Pract. 2021 03; 17(3):e445-e453.
Score: 0.006
-
Needles in a haystack: Extremely rare invasive fungal infections reported in FungiScope?-Global Registry for Emerging Fungal Infections. J Infect. 2020 11; 81(5):802-815.
Score: 0.006
-
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med. 2020 11 05; 383(19):1827-1837.
Score: 0.006
-
Reaction times are faster in HIV-seropositive patients on antiretroviral therapy: A preliminary report. J Clin Exp Neuropsychol. 1999 Oct; 21(5):730-5.
Score: 0.006
-
Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical Trials. Clin Infect Dis. 2019 04 08; 68(8):1420-1426.
Score: 0.006
-
Misdiagnosis of Bordetella bronchiseptica Respiratory Infection as Bordetella pertussis by Multiplex Molecular Assay. Clin Infect Dis. 2018 11 28; 67(12):1919-1921.
Score: 0.006
-
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019 02; 25(2):369-381.
Score: 0.006
-
Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2018 05 26; 391(10135):2116-2127.
Score: 0.005
-
Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species. Mycoses. 2018 Jul; 61(7):485-497.
Score: 0.005
-
Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial. Mycoses. 2018 Jul; 61(7):420-429.
Score: 0.005
-
Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trial. J Antimicrob Chemother. 2018 03 01; 73(3):757-763.
Score: 0.005
-
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. N Engl J Med. 2017 12 21; 377(25):2433-2444.
Score: 0.005
-
Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease. J Antimicrob Chemother. 2017 Dec 01; 72(12):3406-3413.
Score: 0.005
-
The Impact of Recurrent Clostridium difficile Infection on Patients' Prevention Behaviors. Infect Control Hosp Epidemiol. 2017 11; 38(11):1351-1357.
Score: 0.005
-
Acute Myocarditis Secondary to Reactivated Chromosomally-Integrated Human Herpesvirus 6. J Card Fail. 2017 07; 23(7):576-577.
Score: 0.005
-
Serological positive markers of hepatitis B virus in femoral venous blood or umbilical cord blood should not be evidence of in-utero infection among neonates. BMC Infect Dis. 2016 08 12; 16(1):408.
Score: 0.005
-
Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016 Jul; 16(7):828-837.
Score: 0.005
-
Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD Study. Clin Infect Dis. 2016 Mar 01; 62(5):596-602.
Score: 0.005
-
Correlation between Circulating Fungal Biomarkers and Clinical Outcome in Invasive Aspergillosis. PLoS One. 2015; 10(6):e0129022.
Score: 0.004
-
Pharmacokinetics of LFF571 and vancomycin in patients with moderate Clostridium difficile infections. Antimicrob Agents Chemother. 2015 Mar; 59(3):1441-5.
Score: 0.004
-
Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med. 2014 May 08; 370(19):1781-9.
Score: 0.004
-
Reply to M.R. Green et al. J Clin Oncol. 2013 Dec 01; 31(34):4379.
Score: 0.004
-
CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med. 2013 Sep 26; 369(13):1227-36.
Score: 0.004
-
Histoplasmosis after solid organ transplant. Clin Infect Dis. 2013 Dec; 57(11):1542-9.
Score: 0.004
-
Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin. J Clin Oncol. 2013 Jul 01; 31(19):2493-9.
Score: 0.004
-
Herpes zoster and radiation therapy: what radiation oncologists need to know about diagnosing, preventing, and treating herpes zoster. Pract Radiat Oncol. 2014 Jan-Feb; 4(1):58-64.
Score: 0.004
-
Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy. BMC Infect Dis. 2013 Mar 25; 13:148.
Score: 0.004
-
Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. Clin Infect Dis. 2012 Aug; 55 Suppl 2:S121-6.
Score: 0.004
-
Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011 Feb 03; 364(5):422-31.
Score: 0.003
-
Successful nonoperative management of gastrointestinal mucormycosis: novel therapy for invasive disease. Surg Infect (Larchmt). 2009 Oct; 10(5):447-51.
Score: 0.003
-
Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrob Agents Chemother. 2009 Jan; 53(1):223-8.
Score: 0.003
-
Activated neutrophils release mediators that may contribute to myocardial injury and dysfunction associated with ischemia and reperfusion. Ann N Y Acad Sci. 1988; 524:103-21.
Score: 0.003
-
Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant. 2007 Apr; 39(7):425-9.
Score: 0.002
-
Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother. 2006 Jan; 50(1):126-33.
Score: 0.002
-
International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis. 2005 Oct; 24(10):654-61.
Score: 0.002
-
Recombinant urokinase for restoration of patency in occluded central venous access devices. A double-blind, placebo-controlled trial. Thromb Haemost. 2004 Sep; 92(3):575-82.
Score: 0.002
-
Clinical and magnetic resonance imaging regression of progressive multifocal leukoencephalopathy in an AIDS patient after intensive antiretroviral therapy. J Neuroimaging. 2001 Jul; 11(3):336-9.
Score: 0.002
-
Verbal working memory in HIV-seropositive drug users. J Int Neuropsychol Soc. 2000 Jul; 6(5):548-55.
Score: 0.002
-
Reversal of accelerated neutrophil apoptosis and restoration of respiratory burst activity with r-metHuG-CSF (Filgrastim therapy in patients with AIDS. AIDS. 1999 Feb 25; 13(3):427-9.
Score: 0.001
-
Impaired phagocyte oxidative capacity in patients with human immunodeficiency virus infection. J Lab Clin Med. 1998 Oct; 132(4):284-93.
Score: 0.001
-
Information processing and antiretroviral therapy in HIV-1 infection. J Int Neuropsychol Soc. 1998 Jul; 4(4):329-35.
Score: 0.001
-
Working memory deficits in HIV-seropositive drug users. J Int Neuropsychol Soc. 1997 Sep; 3(5):451-6.
Score: 0.001
-
Accelerated neutrophil apoptosis in the acquired immunodeficiency syndrome. J Clin Invest. 1996 Dec 15; 98(12):2714-9.
Score: 0.001
-
Delayed recognition memory span in HIV-1 infection. J Int Neuropsychol Soc. 1995 Nov; 1(6):575-80.
Score: 0.001
-
Spontaneous chemiluminescence of ETYA (5,8,11,14-eicosatetraynoic acid) is inhibited by catalase or peroxidase. Prostaglandins Leukot Essent Fatty Acids. 1994 Oct; 51(4):271-5.
Score: 0.001
-
Adenosine-mediated inhibition of platelet aggregation by acadesine. A novel antithrombotic mechanism in vitro and in vivo. J Clin Invest. 1994 Oct; 94(4):1524-32.
Score: 0.001